Development of a Serogroup B Specific Footrot Vaccine with Montanide ISA 61 VG Adjuvant for Prophylactic and Therapeutic Use in Sheep

Virulent footrot represents as a significant contagious ailment affecting sheep, with Dichelobacter nodosus being the primary agent responsible for transmitting the disease. Vaccinations and various management practices are utilized to control the disease. In this study, we cultured D. nodosus in br...

Full description

Saved in:
Bibliographic Details
Main Authors: Arham Quraishi, Isfaqul Hussain, Shaheen Farooq, Zahid Amin Kashoo, Najeeb Ul Tarfain, Sabia Qureshi, Mir Nadeem Hassan, Mohd Altaf Bhat, Mansoor Nabi Mir, Syed Mudasir Ahmad, Syed Akram Hussain, Zahoor Ahmad Wani
Format: Article
Language:English
Published: Journal of Pure and Applied Microbiology 2025-03-01
Series:Journal of Pure and Applied Microbiology
Subjects:
Online Access:https://microbiologyjournal.org/development-of-a-serogroup-b-specific-footrot-vaccine-with-montanide-isa-61-vg-adjuvant-for-prophylactic-and-therapeutic-use-in-sheep/
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849344011918114816
author Arham Quraishi
Isfaqul Hussain
Shaheen Farooq
Zahid Amin Kashoo
Najeeb Ul Tarfain
Sabia Qureshi
Mir Nadeem Hassan
Mohd Altaf Bhat
Mansoor Nabi Mir
Syed Mudasir Ahmad
Syed Akram Hussain
Zahoor Ahmad Wani
author_facet Arham Quraishi
Isfaqul Hussain
Shaheen Farooq
Zahid Amin Kashoo
Najeeb Ul Tarfain
Sabia Qureshi
Mir Nadeem Hassan
Mohd Altaf Bhat
Mansoor Nabi Mir
Syed Mudasir Ahmad
Syed Akram Hussain
Zahoor Ahmad Wani
author_sort Arham Quraishi
collection DOAJ
description Virulent footrot represents as a significant contagious ailment affecting sheep, with Dichelobacter nodosus being the primary agent responsible for transmitting the disease. Vaccinations and various management practices are utilized to control the disease. In this study, we cultured D. nodosus in broth culture under reducing conditions and formulated a vaccine using Montanide oil as adjuvant. The efficacy of the vaccine was assessed in sheep to determine its ability to elicit an effective immune response and its therapeutic potential. D. nodosus serogroup B (JKS-07B strain) was grown in a modified TAS broth and a whole cell killed vaccine was prepared using 1.5 × 109 cells per dose, along with the oil adjuvant Montanide ISA 61 VG. The vaccine trial was conducted in sheep and two doses of the vaccine were given subcutaneously with a 30 days interval between the doses. The serum antibody titers in the vaccinated animals were measured at 0, 30, 60, 90, 120, and 150 days post-vaccination using the microplate agglutination test. Protective antibody titers (≥ 3000) were achieved by the 30th day following the primary vaccination in all animals, reaching their peak at the 60th day. The protective level of antibody titers was maintained up to 120 days following the primary vaccination. The vaccine also demonstrated a therapeutic effect in animals that were clinically affected. Animals with a lesion score of 2 took 18-21 days for recovery, while those with a lesion score of 3-4 took 40-47 days to recover from lameness.
format Article
id doaj-art-7c5271d197d24f3191dc24832589a2f0
institution Kabale University
issn 0973-7510
2581-690X
language English
publishDate 2025-03-01
publisher Journal of Pure and Applied Microbiology
record_format Article
series Journal of Pure and Applied Microbiology
spelling doaj-art-7c5271d197d24f3191dc24832589a2f02025-08-20T03:42:47ZengJournal of Pure and Applied MicrobiologyJournal of Pure and Applied Microbiology0973-75102581-690X2025-03-01191255262https://doi.org/10.22207/JPAM.19.1.16Development of a Serogroup B Specific Footrot Vaccine with Montanide ISA 61 VG Adjuvant for Prophylactic and Therapeutic Use in SheepArham QuraishiIsfaqul Hussainhttps://orcid.org/0000-0001-6034-9472Shaheen Farooqhttps://orcid.org/0000-0002-8231-6089Zahid Amin Kashoohttps://orcid.org/0000-0001-6962-7256Najeeb Ul TarfainSabia Qureshihttps://orcid.org/0000-0002-7731-3334Mir Nadeem Hassanhttps://orcid.org/0000-0002-8475-0495Mohd Altaf Bhathttps://orcid.org/0000-0003-0961-4829Mansoor Nabi Mirhttps://orcid.org/0009-0006-2177-6336Syed Mudasir Ahmadhttps://orcid.org/0000-0001-6036-6467Syed Akram Hussainhttps://orcid.org/0000-0002-6041-6169Zahoor Ahmad Wanihttps://orcid.org/0000-0002-1352-0334Virulent footrot represents as a significant contagious ailment affecting sheep, with Dichelobacter nodosus being the primary agent responsible for transmitting the disease. Vaccinations and various management practices are utilized to control the disease. In this study, we cultured D. nodosus in broth culture under reducing conditions and formulated a vaccine using Montanide oil as adjuvant. The efficacy of the vaccine was assessed in sheep to determine its ability to elicit an effective immune response and its therapeutic potential. D. nodosus serogroup B (JKS-07B strain) was grown in a modified TAS broth and a whole cell killed vaccine was prepared using 1.5 × 109 cells per dose, along with the oil adjuvant Montanide ISA 61 VG. The vaccine trial was conducted in sheep and two doses of the vaccine were given subcutaneously with a 30 days interval between the doses. The serum antibody titers in the vaccinated animals were measured at 0, 30, 60, 90, 120, and 150 days post-vaccination using the microplate agglutination test. Protective antibody titers (≥ 3000) were achieved by the 30th day following the primary vaccination in all animals, reaching their peak at the 60th day. The protective level of antibody titers was maintained up to 120 days following the primary vaccination. The vaccine also demonstrated a therapeutic effect in animals that were clinically affected. Animals with a lesion score of 2 took 18-21 days for recovery, while those with a lesion score of 3-4 took 40-47 days to recover from lameness.https://microbiologyjournal.org/development-of-a-serogroup-b-specific-footrot-vaccine-with-montanide-isa-61-vg-adjuvant-for-prophylactic-and-therapeutic-use-in-sheep/dichelobacter nodosusantibody titermontanide isa 61 vgvaccinetherapeutic effect
spellingShingle Arham Quraishi
Isfaqul Hussain
Shaheen Farooq
Zahid Amin Kashoo
Najeeb Ul Tarfain
Sabia Qureshi
Mir Nadeem Hassan
Mohd Altaf Bhat
Mansoor Nabi Mir
Syed Mudasir Ahmad
Syed Akram Hussain
Zahoor Ahmad Wani
Development of a Serogroup B Specific Footrot Vaccine with Montanide ISA 61 VG Adjuvant for Prophylactic and Therapeutic Use in Sheep
Journal of Pure and Applied Microbiology
dichelobacter nodosus
antibody titer
montanide isa 61 vg
vaccine
therapeutic effect
title Development of a Serogroup B Specific Footrot Vaccine with Montanide ISA 61 VG Adjuvant for Prophylactic and Therapeutic Use in Sheep
title_full Development of a Serogroup B Specific Footrot Vaccine with Montanide ISA 61 VG Adjuvant for Prophylactic and Therapeutic Use in Sheep
title_fullStr Development of a Serogroup B Specific Footrot Vaccine with Montanide ISA 61 VG Adjuvant for Prophylactic and Therapeutic Use in Sheep
title_full_unstemmed Development of a Serogroup B Specific Footrot Vaccine with Montanide ISA 61 VG Adjuvant for Prophylactic and Therapeutic Use in Sheep
title_short Development of a Serogroup B Specific Footrot Vaccine with Montanide ISA 61 VG Adjuvant for Prophylactic and Therapeutic Use in Sheep
title_sort development of a serogroup b specific footrot vaccine with montanide isa 61 vg adjuvant for prophylactic and therapeutic use in sheep
topic dichelobacter nodosus
antibody titer
montanide isa 61 vg
vaccine
therapeutic effect
url https://microbiologyjournal.org/development-of-a-serogroup-b-specific-footrot-vaccine-with-montanide-isa-61-vg-adjuvant-for-prophylactic-and-therapeutic-use-in-sheep/
work_keys_str_mv AT arhamquraishi developmentofaserogroupbspecificfootrotvaccinewithmontanideisa61vgadjuvantforprophylacticandtherapeuticuseinsheep
AT isfaqulhussain developmentofaserogroupbspecificfootrotvaccinewithmontanideisa61vgadjuvantforprophylacticandtherapeuticuseinsheep
AT shaheenfarooq developmentofaserogroupbspecificfootrotvaccinewithmontanideisa61vgadjuvantforprophylacticandtherapeuticuseinsheep
AT zahidaminkashoo developmentofaserogroupbspecificfootrotvaccinewithmontanideisa61vgadjuvantforprophylacticandtherapeuticuseinsheep
AT najeebultarfain developmentofaserogroupbspecificfootrotvaccinewithmontanideisa61vgadjuvantforprophylacticandtherapeuticuseinsheep
AT sabiaqureshi developmentofaserogroupbspecificfootrotvaccinewithmontanideisa61vgadjuvantforprophylacticandtherapeuticuseinsheep
AT mirnadeemhassan developmentofaserogroupbspecificfootrotvaccinewithmontanideisa61vgadjuvantforprophylacticandtherapeuticuseinsheep
AT mohdaltafbhat developmentofaserogroupbspecificfootrotvaccinewithmontanideisa61vgadjuvantforprophylacticandtherapeuticuseinsheep
AT mansoornabimir developmentofaserogroupbspecificfootrotvaccinewithmontanideisa61vgadjuvantforprophylacticandtherapeuticuseinsheep
AT syedmudasirahmad developmentofaserogroupbspecificfootrotvaccinewithmontanideisa61vgadjuvantforprophylacticandtherapeuticuseinsheep
AT syedakramhussain developmentofaserogroupbspecificfootrotvaccinewithmontanideisa61vgadjuvantforprophylacticandtherapeuticuseinsheep
AT zahoorahmadwani developmentofaserogroupbspecificfootrotvaccinewithmontanideisa61vgadjuvantforprophylacticandtherapeuticuseinsheep